Essenlix Corporation announced the development of the world’s smallest, simplest, and lowest-cost blood count device – iMOST-CBC (instant mobile self-test for complete blood count).
Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.
Abbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions
Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.
Roche is seeking damages and compensation in a U.S. lawsuit against former executives of a Utah-based company, the Swiss drugmaker’s latest case targeting what the company calls fraudulent schemes involving its diabetes test strips.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.
EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.
Israel’s Medial EarlySign, whose machine-learning based technology is meant to help improve patient management, said on Tuesday it raised $30 million, bringing its total funding to $50 million.
A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumor, potentially helping doctors predict which patients may respond best to some immunotherapies.
Quest Diagnostics Inc. will use a more precise method of calculating levels of “bad” LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.